AR089962A1 - Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso - Google Patents
Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y usoInfo
- Publication number
- AR089962A1 AR089962A1 ARP130100420A ARP130100420A AR089962A1 AR 089962 A1 AR089962 A1 AR 089962A1 AR P130100420 A ARP130100420 A AR P130100420A AR P130100420 A ARP130100420 A AR P130100420A AR 089962 A1 AR089962 A1 AR 089962A1
- Authority
- AR
- Argentina
- Prior art keywords
- polymer
- composition
- oil
- emulsion
- ophthalmic pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 abstract 8
- 239000000203 mixture Substances 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 2
- -1 carboxyvinyl Chemical group 0.000 abstract 2
- 239000000839 emulsion Substances 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 abstract 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical group CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 abstract 1
- 229960001160 latanoprost Drugs 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001277 pectin Polymers 0.000 abstract 1
- 239000001814 pectin Substances 0.000 abstract 1
- 235000010987 pectin Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000230 xanthan gum Substances 0.000 abstract 1
- 229920001285 xanthan gum Polymers 0.000 abstract 1
- 235000010493 xanthan gum Nutrition 0.000 abstract 1
- 229940082509 xanthan gum Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica oftálmica estable para el alivio, el tratamiento, el control, la mejoría o la prevención de una afección ocular patológica comprende: (a) un primer polímero, cuya viscosidad cambia con un cambio en una concentración de un electrólito, tal como una sal, cuando se agrega a dicho primer polímero; (b) un segundo polímero que es diferente del primer polímero y que puede modificar la viscosidad del primer polímero; y (c) un aceite. En algunas formas de realización, la composición además comprende un surfactante no iónico. La composición puede formar una emulsión estable de aceite en agua con el almacenamiento, si bien se separa en una fase de aceite y una fase de agua cuando se aplica al ojo. La emulsión puede comprender un ingrediente activo farmacéutico oftálmico disuelto en fase de aceite o de agua. La emulsión puede proporcionar mejorada estabilidad a dicho ingrediente farmacéutico activo. Reivindicación 5: La composición de la reivindicación 4, donde dicho primer polímero comprende un polímero o copolímero de monómeros de carboxivinilo, y dicho segundo polímero comprende un polisacárido polianiónico. Reivindicación 8: La composición de la reivindicación 7, donde dicho polisacárido polianiónico es seleccionado del grupo que consiste en alginato, ácido hialurónico, glucuronoxilomanano, carboximetjlcelulosa, carboxietilcelulosa, glucosaminoglicano, pectina y goma de xantano. Reivindicación 14: La composición de la reivindicación 13, donde dicho ingrediente activo farmacéutico es latanoprost.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597879P | 2012-02-13 | 2012-02-13 | |
| US13/739,018 US9278132B2 (en) | 2012-02-13 | 2013-01-11 | Ophthalmic pharmaceutical compositions and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089962A1 true AR089962A1 (es) | 2014-10-01 |
Family
ID=48946121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100420A AR089962A1 (es) | 2012-02-13 | 2013-02-08 | Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9278132B2 (es) |
| EP (1) | EP2814463B1 (es) |
| JP (1) | JP5898789B2 (es) |
| KR (1) | KR101760990B1 (es) |
| CN (1) | CN104203215B (es) |
| AR (1) | AR089962A1 (es) |
| AU (1) | AU2013219822B2 (es) |
| CA (1) | CA2864417C (es) |
| ES (1) | ES2576113T3 (es) |
| HU (1) | HUE029276T2 (es) |
| MX (1) | MX349169B (es) |
| PL (1) | PL2814463T3 (es) |
| TW (1) | TWI535462B (es) |
| WO (1) | WO2013122801A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| JP6537775B2 (ja) * | 2014-03-10 | 2019-07-03 | 小林製薬株式会社 | 乳化組成物 |
| US10245324B2 (en) | 2014-10-31 | 2019-04-02 | Johnson & Johnson Consumer Inc. | Ophthalmic composition |
| PT3373976T (pt) | 2015-11-10 | 2024-04-02 | Sun Pharmaceutical Ind Ltd | Formulações tópicas e suas utilizações |
| DK3423076T3 (da) | 2016-02-29 | 2024-07-08 | Sun Pharmaceutical Ind Ltd | Topisk cyclosporinholdige formuleringer og anvendelser deraf |
| EP3231417B1 (de) * | 2016-04-15 | 2018-12-05 | Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH | Lagerungsstabile, ophthalmische zusammensetzung |
| RU2019130955A (ru) * | 2017-03-05 | 2021-04-07 | Ресдевко Рисёрч Энд Дивелопмент Ко. Лтд. | Глазные капли для лечения раздражения, не вызванного инфекцией |
| US10933111B2 (en) * | 2019-01-08 | 2021-03-02 | Boston Biotechnology US CORP | Treating dry eye disorders |
| DE102021212692A1 (de) | 2021-11-11 | 2023-05-11 | Ursapharm Arzneimittel Gmbh | Selbstemulgierende öl-in wasser-mikro- oder nanoemulsion so-wie emulgierende zusammensetzung |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US5209927A (en) | 1985-01-23 | 1993-05-11 | Alcon Laboratories, Inc. | Ophthalmic solution |
| EP0459148B1 (en) | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
| US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| ES2094688B1 (es) * | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| DE69807281T2 (de) * | 1997-05-14 | 2003-04-17 | Mitsubishi Chemical Corp., Tokio/Tokyo | Difluprednat enthaltende Zusammensetzungen |
| CN1456157A (zh) | 2002-05-10 | 2003-11-19 | 刘继东 | 左旋氧氟沙星眼用凝胶 |
| CN1180776C (zh) | 2002-12-02 | 2004-12-22 | 刘继东 | 凝胶型氧氟沙星眼膏 |
| WO2005044276A1 (ja) * | 2003-11-07 | 2005-05-19 | Senju Pharmaceutical Co., Ltd. | プロスタグランジン含有医薬組成物 |
| US9161905B2 (en) * | 2005-01-12 | 2015-10-20 | Ocular Research Of Boston, Inc. | Dry eye treatment |
| US7288520B2 (en) * | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| EP1985298A1 (en) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
| PT2437762T (pt) | 2009-06-05 | 2017-11-14 | Allergan Inc | Lágrimas artificiais e usos terapêuticos |
| FR2962044B1 (fr) * | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
| FR2961694B1 (fr) | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US8957048B2 (en) | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
-
2013
- 2013-01-11 US US13/739,018 patent/US9278132B2/en active Active
- 2013-02-07 ES ES13705675.0T patent/ES2576113T3/es active Active
- 2013-02-07 CA CA2864417A patent/CA2864417C/en active Active
- 2013-02-07 WO PCT/US2013/025013 patent/WO2013122801A1/en not_active Ceased
- 2013-02-07 JP JP2014557693A patent/JP5898789B2/ja active Active
- 2013-02-07 HU HUE13705675A patent/HUE029276T2/en unknown
- 2013-02-07 KR KR1020147025124A patent/KR101760990B1/ko active Active
- 2013-02-07 MX MX2014009620A patent/MX349169B/es active IP Right Grant
- 2013-02-07 AU AU2013219822A patent/AU2013219822B2/en active Active
- 2013-02-07 CN CN201380017182.7A patent/CN104203215B/zh active Active
- 2013-02-07 EP EP13705675.0A patent/EP2814463B1/en active Active
- 2013-02-07 PL PL13705675.0T patent/PL2814463T3/pl unknown
- 2013-02-08 AR ARP130100420A patent/AR089962A1/es unknown
- 2013-02-08 TW TW102105194A patent/TWI535462B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130210912A1 (en) | 2013-08-15 |
| CN104203215A (zh) | 2014-12-10 |
| JP2015507010A (ja) | 2015-03-05 |
| JP5898789B2 (ja) | 2016-04-06 |
| CA2864417A1 (en) | 2013-08-22 |
| PL2814463T3 (pl) | 2016-11-30 |
| TW201345564A (zh) | 2013-11-16 |
| US9278132B2 (en) | 2016-03-08 |
| KR20140121479A (ko) | 2014-10-15 |
| MX349169B (es) | 2017-07-17 |
| EP2814463A1 (en) | 2014-12-24 |
| AU2013219822B2 (en) | 2016-01-14 |
| CN104203215B (zh) | 2017-04-12 |
| MX2014009620A (es) | 2014-11-10 |
| HUE029276T2 (en) | 2017-02-28 |
| CA2864417C (en) | 2018-10-16 |
| KR101760990B1 (ko) | 2017-07-24 |
| AU2013219822A1 (en) | 2014-08-28 |
| TWI535462B (zh) | 2016-06-01 |
| EP2814463B1 (en) | 2016-05-18 |
| ES2576113T3 (es) | 2016-07-05 |
| WO2013122801A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089962A1 (es) | Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso | |
| JP6527468B2 (ja) | ヒアルロン酸ナトリウムとカルボキシメチルセルロースを含む人工涙液 | |
| WO2013037479A8 (en) | Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
| RU2018102693A (ru) | Офтальмологические композиции, содержащие кооперативные комплексы низко- и высокомолекулярной гиалуроновой кислоты | |
| WO2013171204A3 (de) | Ophthalmologisches vehikelsystem | |
| NZ602405A (en) | A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions | |
| BR112014017650A8 (pt) | Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson | |
| FI2887923T3 (fi) | Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito | |
| WO2016172712A3 (en) | Ophthalmic composition | |
| EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
| JP2010540619A5 (es) | ||
| BR112015017246A2 (pt) | formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel | |
| RU2017146716A (ru) | Способ образования наночастиц циклоспорина а/ циклодекстрина | |
| JP2013525335A5 (es) | ||
| WO2012061045A3 (en) | Methods and compositions for preserving retinal ganglion cells | |
| RU2012103538A (ru) | Композиции и способы ингибирования пути jak | |
| EA201201239A1 (ru) | Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением | |
| BR112012033052A2 (pt) | suspensões oftálmicas tópicas contendo tobramicin e dexametasona | |
| RU2014127074A (ru) | Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы | |
| BR112013022237A2 (pt) | uso de fluido viscoelástico para produzir produto medicinal para tratar cirurgicamente o olho | |
| BR112014031463A2 (pt) | composição pesticida na forma de emulsão aquosa | |
| RU2016136333A (ru) | Фармакологическая офтальмологическая композиция, используемая в коррекции пресбиопии, и ее введение | |
| RU2724955C2 (ru) | Офтальмологическая композиция, содержащая липоевую кислоту и мукомиметический полимер | |
| RU2013152013A (ru) | Офтальмологическая композиция с системой увеличения вязкости, имеющей два различных увеличивающих вязкость агента | |
| WO2014179799A3 (en) | Retina extracellular matrix based biomaterial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |